17 July 2023 | Monday | News
Image Source | Public Domain
Modi Ventures, a newly launched venture partnership investing in fund managers and founders building companies shaping the future of humanity, today announced the close of its inaugural $32 million fund, Tech+Bio Fund I. The new fund will target innovative companies transforming business in Tech Bio, life science and healthcare AI. Despite the challenging investment economy, the fund was raised in a short period of time and oversubscribed by $2 million. Andrew Yang, former presidential candidate and founder of Venture for America was named an advisor.
Modi Ventures was founded by Sahir Ali, a researcher, scientist and technologist recognized as a thought leader in the precision medicine and AI space. Sahir, who has a Ph.D. focused on the intersection of oncology and AI, has advised and led F500 companies in the healthcare, AI, and enterprise tech industries.
"Investing in next generation technologies has always been very lucrative," said Sahir Ali, General Partner with Modi Ventures. "We are entering an era of software writing software (artificial intelligence), technology that can unravel our individual genetic makeup (gene sequencing), biotech that can reprogram our genes (gene editing), and a fundamental change in how medicine is practiced by leveraging all of the above (precision medicine). Tech Bio companies will revolutionize multiple trillion dollar industries, providing early investors with potential for great returns."
The fund aims to invest into opportunities such as Tech Bio where companies are creating exponential technologies that are on the cusp of transforming health and technology. Tech Bio utilizes AI to analyze complex, heterogeneous information to disrupt and revolutionize the practice of medicine and delivery of health. This has immense potential in revolutionizing clinical trial design, drug development and precision medicine. McKinsey estimates that Tech Bio has the potential to transform the global economy with $2 trillion to $4 trillion of direct annual impact, where Tech Bio innovations could produce 60% of the world's physical goods inputs and ease 45% of the world's disease burden.
"Modi Ventures' goal is to find solutions for some of the world's most vexing problems that keep people unhealthy or struggling with illnesses that we can address collectively," said Andrew Yang, Founder of Forward Party and Venture for America, and Advisor to Modi Ventures. "The leadership and results that Sahir and his team have already demonstrated are one reason I'm looking forward to being a part of this team as we bring life saving solutions to market and take advantage of AI and new tools to advance the human condition."
Modi Ventures has created partnerships with successful funds such as Khosla Ventures, Section 32, Artis Ventures, Draper Associates and Antler Group.
Initial Investments by the Tech+Bio Fund I include
"Modi Ventures is investing in healthcare tech companies with immense potential to improve lives and I'm thrilled to be partnering with Sahir and Modi Ventures," said Tim Draper, Founder, Draper Associates. "Working together we will be able to discover unique and innovative investments to collaborate on."
© 2024 Biopharma Boardroom. All Rights Reserved.